CDT Equity partners with QIMA Life Sciences to study tapinarof combination therapies in psoriasis and vitiligo

CDT•2026-09-18

Partnership to evaluate tapinarof combinations

CDT Equity entered a partnership with QIMA Life Sciences to evaluate novel tapinarof combination therapies in autoimmune skin diseases.

Initial work targets plaque psoriasis, using human psoriatic skin to support development of a second-generation tapinarof topical with improved efficacy.

Studies will also assess tapinarof combinations in vitiligo, which affects about 0.5%-2.0% of the global population.

The vitiligo drug market is estimated at about US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 2030.

CDT Equity partners with QIMA Life Sciences to study tapinarof combination therapies in psoriasis and vitiligo

Partnership to evaluate tapinarof combinations

Related News

Pentair appoints ex-Regal Rexnord CEO Louis Pinkham to board, names him to audit and finance committee

Global equity fund outflows hit nine-month high on inflation fears

UBS lifts total Renk stake to 5.08% voting rights

CrowdStrike <CRWD.O>: Stephens raises target price to $280 from $260

Xenon Pharmaceuticals Inc. <XENE.O>: Wedbush cuts target price to $55 from $71